期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

微粒化非诺贝特对老年人血脂代谢紊乱的疗效观察 被引量：1

暂未订购
导出
摘要 目的观察微粒化非诺贝特对老年人血脂代谢紊乱的疗效及安全性。方法血脂代谢紊乱的老年人120例,随机分为3组,非诺贝特组40例服用力平脂200mg/d,辛伐他汀组40例服用辛伐他汀20mg/d,安慰剂组40例,8周后观察血脂成分的变化。结果微粒化非诺贝特能有效降低血清总胆固醇,三酰甘油,低密度脂蛋白胆固醇,并能显著升高高密度脂蛋白胆固醇,明显降低血尿酸。辛伐他汀能有效降低血清总胆固醇,对血脂其他成分的疗效不及非诺贝特。二者临床安全性无差异。结论微粒化非诺贝特用于治疗老年人血脂代谢紊乱疗效好,安全、耐受性好,易于接受。
作者 孙学春
机构地区 四川省人民医院
出处 《四川医学》 CAS 2005年第9期975-976,共2页 Sichuan Medical Journal
关键词 微粒化非诺贝特 老年人 血脂代谢紊乱
分类号 R589.2 [医药卫生—内分泌]
  • 相关文献

参考文献5

  • 1方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量：3068
  • 2Griffin BA, Freemen DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein to coronary heart disease risk[J]. Atherosclerosis, 1994,16:241 - 253.
  • 3Sommariva D,Bonfiglioli D, Pogliaghi I, et al. Fenofibrate therapy of hypertriglyceridaemias,differenrial effects on LDL cholesterol level in type a and in type b primary hyperlipoproteinaemia [ J]. Eur J Clin Pharmacol,1984,26:741.
  • 4陈斌,韩琴琴,陈曙霞,梅尚义,胡义桥,陈淑良.吉非贝齐与非诺贝特降脂疗效比较[J].新药与临床,1995,14(2):77-79. 被引量：12
  • 5诸骏仁,叶平,寇文镕,戚文航,马虹.微粒化非诺贝特治疗血脂异常的疗效与耐受性研究[J].中华心血管病杂志,2002,30(3):152-155. 被引量：17

二级参考文献9

  • 1Rubins HB,Robins SJ,Collins D,et al.Gemfibrozil for the second prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol.Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Intervention Trial Study Group[].The New England Journal of Medicine.1999
  • 2Sacks FM,Pfeffer MA,Moye LA,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events Trial investigators[].The New England Journal of Medicine.1996
  • 3Shepherd J,Cobbe SM,Ford I,et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.West of Scotland Coronary Prevention Study Group[].The New England Journal of Medicine.1995
  • 4Kirchgassler KU,Schmitz H,Bach G,et al.Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidemia[].Clinical Drug Investigation.1998
  • 5Kornitzer M,Dramaix M,Vandenbroek MD,et al.Efficacy and tolerance of 200mg micronized fenofibrate administered over 6-month period in hyperlipidaemic patients: an open Belgian multicenter study[].Atherosclerosis.1994
  • 6Miller M,Seidler A,Kwiterovich PO,et al.Long-term predictors of subsequent cardiovascular events with coronary artery disease and"desirable"levels of plasma total cholesterol[].Circulation.1992
  • 7Auwerx J,Schoonjans K,Fruchart JC,et al.Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apoC-III genes by activating the nuclear receptor PPAR[].Atherosclerosis.1996
  • 8Gordon DJ,Probstfield JL,Garrison RJ,et al.High-density lipoprotein cholesterol and cardiovascular disease.Four prospective American studies[].Circulation.1989
  • 9诸骏仁,韩琴琴,陈斌,庄汉忠,严秀萍.吉非罗齐对高脂血症患者的疗效观察[J].上海医学,1990,13(4):227-228. 被引量：2

共引文献3089

同被引文献8

引证文献1

二级引证文献1

四川医学
2005年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部